SCHEMBL20037883

SCHEMBL20037883

Cn1cc(-c2ccc(I)nc2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
GPR55 Q9Y2T6 1/20 0.46
LRRK2 Q5S007 1/20 0.44
ACVR1 Q04771 1/20 0.42
FLT3 P36888 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.40
CLK1 P49759 1/20 0.40
IRAK1 P51617 1/20 0.40
MAP4K4 O95819 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.39
CHEK1 O14757 1/20 0.39
CHEK2 O96017 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9290133 0.79 LRRK2 (0.49) MAPTGPR55LRRK2ACVR1FLT3
SCHEMBL22917028 0.79 MKNK1 (0.47) LRRK2ACVR1MKNK1MKNK2PIK3CD
SCHEMBL30519697 0.78 MAPT (0.47) MAPTGPR55LRRK2ACVR1FLT3
SCHEMBL27252273 0.78 MAPT (0.47) MAPTGPR55LRRK2ACVR1FLT3
SCHEMBL8184158 0.78 PIK3CD (0.48) MAPTGPR55LRRK2ACVR1FLT3
SCHEMBL14783930 0.78 GPR55 (0.52) MAPTGPR55LRRK2ACVR1FLT3
SCHEMBL3387141 0.78 KIT (0.56) MAPTGPR55LRRK2FLT3MKNK1
SCHEMBL21255068 0.75 GPR55 (0.57) MAPTGPR55LRRK2ACVR1CLK1
SCHEMBL17212043 0.75 MAPT (0.45) MAPTGPR55LRRK2ACVR1FLT3
SCHEMBL30519619 0.75 CYP2A6 (0.50) MAPTGPR55LRRK2MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4227304-A2 THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS Novartis AG (CH) 2023-08-16 EP disclosed
EP-3736271-A1 THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS Novartis AG (CH) 2020-11-11 EP disclosed
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed
EP-3305785-A1 PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Teijin Pharma Limited (JP) 2018-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 MAPT 2551/4885GPR55 2044/4885LRRK2 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.